An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

SIMPLE SUMMARY: Microsatellite instability-high (MSI-H) is an established biomarker for response to immune checkpoint inhibitors (ICIs). ICIs are not usually administered in the first-line setting for MSI-H tumors including gastric cancer (GC), although such tumors tend to be less responsive to cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Hisato, Hironaka, Shuichi, Esaki, Taito, Chayama, Kazuaki, Tsuda, Masahiro, Sugimoto, Naotoshi, Kadowaki, Shigenori, Makiyama, Akitaka, Machida, Nozomu, Hirano, Hidekazu, Hirata, Kenro, Hara, Hiroki, Yabusaki, Hiroshi, Komatsu, Yoshito, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918984/
https://www.ncbi.nlm.nih.gov/pubmed/33671871
http://dx.doi.org/10.3390/cancers13040805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918984/
https://www.ncbi.nlm.nih.gov/pubmed/33671871
http://dx.doi.org/10.3390/cancers13040805

Ejemplares similares